Tag: ICRA
Budget FY 2026-27: Medical tourism & biopharma push to strengthen healthcare...
Higher healthcare allocation, establishment of medical tourism hubs and Biopharma Shakti programme expected to enhance patient access, research capacity and sectoral growth
ICRA retains positive outlook on hospitals, stable on pharma
Hospital sector revenue seen growing 16-18% in FY2026; Pharma revenue projected to expand 9-11%
Indian pharma firms set for 7–9% revenue growth in FY26 despite...
ICRA maintains a stable outlook on the pharmaceuticals sector, supported by sustained demand in both domestic and export markets
ICRA revises hospital sector outlook to positive; Rs 32,000 crore capex...
Forecasts strong growth for India’s hospital industry with 14,500 new beds and robust ARPOB, OPM, and RoCE in FY2026
Indian hospital industry to add over 7,400 beds by FY2026: ICRA
ICRA forecasts a 12-14% revenue growth for Indian hospitals in FY2025, driven by capacity expansion and strong demand
Credit profile of Indian pharma companies to remain healthy in FY2025:...
Revenue growth to moderate to 8-10% in FY2025, post a healthy 13-14% YoY expansion in FY2024
Private hospital players expected to invest Rs 32,500 crore for adding...
Operating profit margin for ICRA’s sample set companies to remain healthy at over 22% in FY2024 supported by operating leverage and continued benefits from cost optimization measures
Indian hospital industry to remain strong in 2024, predicts ICRA
ICRA expects occupancy of its sample set to remain flattish at 64-65% in FY2024, while the ARPOB is expected to expand by 8-9%
Indian hospital industry in the pink of health: ICRA
Operating profit margin will remain healthy at over 22% in FY2024, supported by operating leverage and continued benefits from cost optimization measures
Majority of pharma industry to grow at 7-9% in FY2024: ICRA
USFDA inspections have gained momentum in the recent past and regulatory risks remain a key monitorable